I believe people increasingly skip the waiting room: telehealth subscriptions, mRNA platforms that iterate like software, and consumer brands built around wellness. This basket owns that shift from the provider side and the brand side, weighted toward the direct-to-consumer leader.
What would change my mind: Regulators clamp down on compounded and telehealth-prescribed drugs.
No replies yet. Bull or bear, say why.